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Abstract
DNA interstrand crosslinks (ICLs) are among the most toxic types of damage to a cell. For this reason, many ICL-inducing
agents are effective therapeutic agents. For example, cisplatin and nitrogen mustards are used for treating cancer and
psoralen plus UVA (PUVA) is useful for treating psoriasis. However, repair mechanisms for ICLs in the human genome are not
clearly defined. Previously, we have shown that MSH2, the common subunit of the human MutSa and MutSb mismatch
recognition complexes, plays a role in the error-free repair of psoralen ICLs. We hypothesized that MLH1, the common
subunit of human MutL complexes, is also involved in the cellular response to psoralen ICLs. Surprisingly, we instead found
that MLH1-deficient human cells are more resistant to psoralen ICLs, in contrast to the sensitivity to these lesions displayed
by MSH2-deficient cells. Apoptosis was not as efficiently induced by psoralen ICLs in MLH1-deficient cells as in MLH1-
proficient cells as determined by caspase-3/7 activity and binding of annexin V. Strikingly, CHK2 phosphorylation was
undetectable in MLH1-deficient cells, and phosphorylation of CHK1 was reduced after PUVA treatment, indicating that
MLH1 is involved in signaling psoralen ICL-induced checkpoint activation. Psoralen ICLs can result in mutations near the
crosslinked sites; however, MLH1 function was not required for the mutagenic repair of these lesions, and so its signaling
function appears to have a role in maintaining genomic stability following exposure to ICL-induced DNA damage.
Distinguishing the genetic status of MMR-deficient tumors as MSH2-deficient or MLH1-deficient is thus potentially
important in predicting the efficacy of treatment with psoralen and perhaps with other ICL-inducing agents.
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Introduction
A DNA interstrand crosslink (ICL) is a type of DNA damage in
which both strands of the DNA are covalently linked. ICLs present
formidable challenges to the cell’s essential DNA metabolic
processes including replication and transcription. DNA cross-
linking agents, e.g., psoralens, mitomycin C (MMC), platinum
drugs, and nitrogen mustards, are among the most effective
anticancer agents and are commonly included in combination
chemotherapy regimens. The formation of covalent crosslinks is a
critical event for the cytotoxicity and antitumor activity of these
ICL-inducing agents [1]. Herbs that are rich in psoralens have
been used for centuries to treat vitiligo and other skin disorders;
and in modern medicine, psoralen is widely used in conjunction
with ultraviolet A (UVA) irradiation [psoralen+UVA (PUVA)] for
treatment of several skin disorders including psoriasis, mycosis
fungoides, eczema, vitiligo and skin cancer [2]. UVA is ultraviolet
light with a wavelength between 315–400 nm. While PUVA-
induced ICLs have been extensively studied, the mechanism(s) of
ICL processing in mammalian cells is still not well defined.
Current evidence suggest that proteins from several DNA repair
pathways are involved in the processing of ICLs in mammalian
cells, including proteins with roles in nucleotide excision repair
(NER), mismatch repair (MMR), and homologous recombination
(HR) mechanisms [3–5]. As in bacteria and yeast, it is proposed
that there is a major recombination-dependent error-free pathway
and a minor recombination-independent error-generating path-
way of ICL repair in human cells [3,6]. However, the molecular
details of these pathways are not yet clearly defined.
Triplex-forming oligonucleotides (TFOs) are single-stranded
oligonucleotides that can bind to purine-rich stretches of duplex
DNA via Hoogsteen hydrogen bonding in a sequence-specific
manner. Psoralen-modified TFOs can induce site-specific psoralen
ICLs at the duplex-triplex junction in both plasmid and genomic
DNA [5,7–9]. Studies employing this site-specific ICL model and
others have demonstrated that NER proteins specifically recognize
DNA-ICL lesions and are involved in an error-generating pathway
of ICL repair [10–14], while the MMR protein MSH2 participates
in the error-free repair of psoralen ICLs [3,5,6].
The DNA MMR system is essential for maintaining genomic
stability and preventing tumor formation, and is highly conserved
in evolution. MMR is responsible for correcting DNA replication
errors and processing heteroduplex regions in HR intermediates
[15–18]. In humans, the initial step of MMR is recognition of
mismatches by one of two heterodimers, MutSa (MSH2 and
MSH6) or MutSb (MSH2 and MSH3). In the subsequent step, the
mismatch bound by MutSa or MutSb recruits a MutL complex, of
which MLH1 is an essential component. It is thought that the
PLoS Genetics | www.plosgenetics.org 1 September 2008 | Volume 4 | Issue 9 | e1000189MutS/MutL complex slides along the DNA until it encounters a
strand break, and then loads exonuclease I to degrade the DNA
strand containing the mispaired base. The resulting gap is then
filled by Polymerase d [19].
MMR recognition complexes can interact with several DNA
lesions that are normally repaired by direct reversal, base excision
repair, or NER; e.g. T-T cis-syn-cyclobutane pyrimidine dimers
[20,21], T-T 6-4 photoproducts [21], 8-oxoguanine [22,23], O
6-
methylguanine [24,25], O
4-methylthymine [25], cisplatin intras-
trand crosslinks [26,27], and psoralen ICLs [4,5].
MMR proteins have been shown to play a role in cell death in
response to N-methyl-N9-nitro-N-nitrosoguanidine, 6-thioguanine,
cisplatin, carboplatin, and B[a]P [28–31]. Recent studies show
that MMR proteins are required for S-phase checkpoint activation
induced by ionizing irradiation [32], and G2-checkpoint activation
induced by cisplatin, SN1 DNA methylators, and 6-thioguanine
[33–39]. Exposure to SN1 DNA methylators has been reported to
activate MSH2- and MLH1-dependent phosphorylation of CHK1
through ATR [36,37]. However, the function of MMR proteins in
signaling cellular responses to psoralen ICLs has not been defined.
Psoralen ICLs arrest human cells at S phase [40] by active
checkpoint signaling [41]. Studies reveal that ATM and ATR may
function as sensors in response to psoralen ICL exposure. The
ICL-activated S-phase checkpoint depends on ATR-CHK1 and
ATR-NBS1-FANCD2 pathways [42].
We have shown that MSH2, the common subunit of MutSa and
MutSb mismatch recognition complexes, plays a role in the error-
freerepairofpsoralenICLs[5].Thus, wehypothesizedthatMLH1,
the common subunit of human MutL complexes, is also involved in
the cellular response to psoralen ICLs. Interestingly, we found that
MLH1-deficient human cells are more resistant to psoralen ICLs,
which is different from the MSH2-deficiency which results in
sensitivity to this lesion [5]. We measured the apoptotic status of
human MLH1-proficent and MLH1-deficient cells following
induction of psoralen ICLs by caspase-3/7 activity and binding of
annexin V, and found that in cells lacking MLH1 function,
apoptosis was not as efficiently induced by psoralen ICLs as in
MLH1-proficient cells. We also found that MLH1-deficient cells
have reduced phosphorylationof CHK1 and CHK2 after induction
of psoralen ICLs, suggesting that MLH1 is involved in signaling
psoralen ICL-induced checkpoint activation. Importantly, MLH1
function is not required for the mutagenic repair of psoralen ICLs,
suggesting it may have a role in maintaining genomic stability
following exposure to ICL-induced DNA damage.
Results
MLH1-Deficient Human Cells Are Resistant to PUVA
Treatment
To determine if MLH1 plays a role in processing psoralen-
crosslinked DNA in human cells, we performed a cell viability
assay following DNA damage induced by PUVA [cells were
exposed to the psoralen derivative, 49-hydroxymethyl-4,59,8-
trimethylpsoralen (HMT), at concentrations ranging from 10
28
to 10
25 M, and UVA irradiated at 1.8 J/cm
2] in MLH1-
proficient (A2780) and isogenic MLH1-deficient (A2780/cp70)
ovarian cancer cells. Cell viability was measured 48 hours after
PUVA treatment. The results shown in Figure 1A demonstrate
that MLH1-deficient cells are ,3-fold more resistant to PUVA
treatment than MLH1-proficient cells at HMT concentrations
between 10
27 and 10
26 M. Results from clonogenic assays also
confirmed that MLH1-deficient A2780/cp cells showed a greater
survivability after PUVA treatment than MLH1-proficient A2780
cells (Figure 1B).
To investigate whether this result was cell line specific, we used
MLH1-specific siRNA oligonucleotides to reduce the level of
MLH1 expression in human cervical cancer HeLa cells.
Treatment of HeLa cells with 100 nM MLH1-specific siRNA
oligonucleotides substantially reduced (,70–90%) the level of
MLH1 protein as assessed by western blotting (Figure S1A; see
Text S1). Twenty-four hours after MLH1-specific or control
siRNA treatment, HeLa cells were treated with HMT (from 10
29
to 10
25 M) and UVA irradiated at 1.8 J/cm
2. Cell viability was
measured 48 hours after treatment. Reduction in the level of
MLH1 by siRNA oligonucleotide treatment rendered HeLa cells
more resistant to psoralen ICLs when treated with 10
27 or
10
26 M HMT and UVA irradiation (Figure S2), consistent with
the results obtained using the isogenic-paired A2780 cells under
similar conditions.
Apoptosis Is Not Efficiently Induced in MLH1-Deficient
Cells in Response to PUVA Treatment
The difference in viability between MLH1-proficient and
MLH1-deficient cells after exposure to PUVA led us to study
the mechanism of cell death induced by this treatment. Apoptosis
efficiency was determined by caspase-3/7 activity in PUVA
treated MLH1-proficient and MLH1-deficient human cells
48 hours after treatment. As shown in Figure 2A, PUVA
treatment induced apoptosis more effectively in the MLH1-
proficient A2780 cells than in the MLH1-deficient cells. This
finding suggests that MLH1 plays an important role in psoralen
ICL-induced apoptosis. Unlike MLH1, MSH2 function is not
required for psoralen ICL-induced apoptosis. Treatment with
HMT (at 1610
26 M) plus UVA irradiation at 1.8 J/cm
2 induced
apoptosis in both the MSH2-proficient HEC59+Chr2 cells and in
the isogenic MSH2-deficient HEC59 cells 48 hours after treat-
ment (Figure 2B).
In order to determine the percentage of cells undergoing
apoptosis after exposure to psoralen ICLs, flow cytometric-based
annexin V-FITC–binding analyses were performed in MLH1-
proficient and -deficient human cells treated with 1610
26 M
HMT and then irradiated with UVA at 1.8 J/cm
2. The results
Author Summary
Crosslinks, linking the complementary stands of the DNA
double helix, can lead to cell death, because they are so
effective at interfering with normal genomic transactions
such as DNA replication. This property of crosslinking
agents has long been utilized in cancer therapy. The
purpose of our research is to understand the function of
DNA repair proteins in cellular responses to DNA
interstrand crosslinking agents. MSH2 is a central protein
in the recognition of DNA mismatches, and we previously
found that it plays an important role in protecting cells
against the toxicity of crosslinks. The MLH1 protein
functions in DNA mismatch repair in a later step, and we
hypothesized that MLH1 may also be involved in repair of
crosslinks. We were surprised to find that MLH1 function is
important for DNA crosslink-induced signaling, rather than
DNA repair. MLH1-deficient cells are more resistant to
crosslinks and have defective signaling to processes that
signal cell death. This work may have clinical consequenc-
es, as mutations in MSH2 and MLH1 are common in
tumors. MSH2-deficient cells may be more vulnerable to
DNA crosslink-inducing agents than normal, while MLH1-
deficient cells have a greater potential to survive cross-
linking treatment, which could instead potentiate further
tumor initiation.
Roles of MMR Proteins in DNA Crosslink Repair
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apoptosis in ,62% of the A2780 cells 48 hours after induction of
psoralen ICLs. In contrast, in the MLH1-deficient cells, only ,5%
of the treated cells had undergone apoptosis 48 hours after
treatment. In the untreated control cells, ,12% of the MLH1-
proficient cells and ,7% of the MLH1-deficient cells had
undergone apoptosis. These data demonstrate that apoptosis is
not efficiently induced in the A2780/cp70 MLH1-deficient cells
after PUVA treatment. This result is consistent with the lack of
caspase-3/7 activation in the A2780/cp70 cells treated in a similar
fashion. We performed a similar assay in the MSH2-proficient and
deficient human cells. As shown in Figure 3B, treatment with
HMT (at 1610
26 M)+UVA at 1.8 J/cm
2, induced apoptosis in
,15% of the HEC59+Chr2 cells and in ,24% of the MSH2-
deficient HEC59 cells 48 hours after induction of psoralen ICLs.
In the untreated control cells, only approximately 5% of the
MSH2-proficient or the MSH2-deficient cells had undergone
apoptosis. These results confirmed that MLH1, but not MSH2
function is important for psoralen ICL-induced apoptosis.
MLH1 Plays an Important Role in Signaling Psoralen ICL-
Induced Checkpoint Activation
PUVA treatment can induce an S-phase cell cycle checkpoint in
human cells [40]. The ICL-activated S-phase checkpoint depends
on ATR-CHK1 and ATR-NBS1-FANCD2 pathways [42]. To
determine if MLH1 function is involved in psoralen ICL-induced
checkpoint signaling, we investigated the phosphorylation activa-
tion of ATR (assessed by phosphorylation at Ser428), CHK1 (at
Ser345), ATM (at Ser1981), and CHK2 (at Thr68) in MLH1-
proficient and MLH1-deficient human cells with or without
Figure 1. Sensitivity of MLH1-proficient or MLH1-deficient cells to PUVA treatment. (A) Viability curves are shown for MLH1+ (A2780) or
MLH12 (A2780/cp70) cells treated with PUVA. The bars represent the standard errors of the means. **p,0.001, *p,0.01. (B) Results from clonogenic
assays are shown for the same cells treated with PUVA.
doi:10.1371/journal.pgen.1000189.g001
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26 M HMT+1.8 J/cm
2). Phosphorylation
of ATR (Ser428), CHK1 (Ser345), ATM (Ser1981) and CHK2
(Thr68) were observed at 1 hour following PUVA treatment in
MLH1-proficient cells as shown in Figure 4. Interestingly, the
phosphorylation level of ATR (Ser428) and CHK1 (Ser345) in
MLH1-deficient cells was much lower than that detected in the
MLH1-proficient cells (Figure 4). Strikingly, psoralen ICL-induced
CHK2 phosphorylation was not detected in the MLH1-deficient
cells, while similar levels of phosphorylation of ATM (Ser1981)
were observed in both MLH1-proficient and MLH1-deficient cells
(Figure 4). These results suggest that MLH1 participates in
signaling ATR, CHK1, and CHK2 activation in response to
psoralen ICLs in human cells.
MLH1, Unlike MSH2, Is Not Directly Required for the
Processing of Triplex-Directed Psoralen ICLs
We have reported previously that MSH2 is directly involved in
the processing of psoralen ICLs [5]. To determine whether MLH1
protein function is required for the processing of psoralen ICLs, we
subjected a psoralen crosslinked pSupFG1 plasmid to cell-free
extracts either proficient or deficient in MLH1 function, together
with [a-
32P]dCTP, unlabelled dNTPs, and an ATP-regenerating
system. Incorporation of radioactive dCTP into the vicinity of the
ICL site indicates the occurrence of DNA repair synthesis. We
found that a psoralen ICL induced similar levels of nucleotide
incorporation into the 188 bp fragment containing the ICL site in
both MLH1-proficient and MLH1-deficient cell extracts (Figure
S3). Thisfindingsuggeststhat the ICL-induced repairsynthesis does
not depend on MLH1 function under the conditions of our assay.
MLH1 Is Not Required for Psoralen ICL-Induced
Mutagenesis
Psoralen ICLs can induce mutations in the DNA of both
prokaryotic and eukaryotic cells [9,43–46]. Since we have
demonstrated that MLH1 deficiency reduces the loss of viability
of cells exposed to psoralen ICLs, it is important to determine if
MLH1 plays a role in the mutagenesis induced by these lesions. To
examine whether MLH1 is involved in the error-generating repair
of psoralen ICLs, we transfected psoralen-crosslinked pSupFG1
mutation reporter plasmids into MLH-proficient and -deficient
human cells. Psoralen conjugated TFOs were used to direct a site-
specific psoralen ICL into the supF mutation-reporter gene on the
pSupFG1 plasmid. pAG30 is a psoralen conjugated TFO that binds
specifically to supF gene sequences and can direct formation of ICLs
at a specific site upon UVA irradiation. pSCR30 is a control TFO
having the same base composition as pAG30, but in a scrambled
sequence and so does not induce specific ICLs in the supF gene.
Forty-eight hours after the cells were transfected with the ICL-
damaged plasmids, DNA was isolated and digested with DpnI.
DpnI is a restriction enzyme specific for methylated GATC sites,
such that those plasmids that did not undergo replication in the
mammalian cells will be digested by this enzyme and removed from
further analysis. Next, plasmids were transfected into MB7070 cells,
a supF mutation indicator strain of E. coli, to screen for supF gene
mutations generated in the human cells. The background mutation
frequency of the supF gene was 0.02% in MLH1-proficient ovarian
cancer cells. As shown in Figure 5, the mutation frequency in the
psoralen-crosslinked pSupFG1 plasmids recovered from MLH1-
proficient cells was 2.9%, which is ,120-fold greater than the
background mutation frequency. In the MLH1-deficient cells, the
background mutation frequency was 0.04%. When the psoralen-
crosslinked pSupFG1 plasmids were processed in the MLH1-
deficient cells, the mutation frequency was 5.6%, which is ,130-
fold greater than the background mutation frequency. In both
MLH1-proficient and MLH1-deficient cells, psoralen ICLs can
inducemutations morethan 120-foldoverbackgroundlevels.These
data suggestthatMLH1functionisnotrequiredforthemutagenesis
induced by psoralen ICLs in these cell lines.
The psoralen-crosslinked plasmids were also transfected into HeLa
cells treated twice with MLH1-specific siRNA or control siRNA
oligonucleotides, which resulted in undetectable levels of MLH1 as
assessed by western blotting. MLH1 protein expression was reduced
to below detectable levels during the 72 hour course of the assay
(Figure S1B). The mutation frequencies of plasmids recovered from
each treatment group are shown in Figure S4. In the untreated HeLa
cells, the psoralen-ICL induced mutation frequency was 3.6%, which
is ,140-fold higher than the background mutation frequency of the
untreated plasmid. In the control siRNA treated cells, the psoralen-
ICL induced mutation frequency was ,65-fold higher than the
background level. The psoralen-crosslinked plasmids induced a
mutation frequency ,67-fold higher than the background frequency
in the MLH1-specific siRNA treated cells, which is comparable to
Figure 2. Caspase-3/7 activation in MLH1-deficient or MSH2-
deficient human cells in response to PUVA treatment. (A) MLH1+
(A2780), MLH12 (A2780/cp70); (B) MSH2+ (HEC59+Chr2), MSH22
(HEC59) cells. The relative level of caspase-3/7 activity is shown for
cells 48 hours after PUVA treatment. Caspase-3/7 activation was
determined by cleavage of a caspase-3/7 substrate and performed in
triplicate. The bars represent the standard errors of the means.
doi:10.1371/journal.pgen.1000189.g002
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PLoS Genetics | www.plosgenetics.org 4 September 2008 | Volume 4 | Issue 9 | e1000189Figure 3. FACS Analysis of apoptotic cells after PUVA treatment in MLH1-deficient or MSH2-deficient human cells. (A) MLH1+ (A2780),
MLH12 (A2780/cp70); (B) MSH2+ (HEC59+Chr2), and MSH22 (HEC59) cells were treated with 1610
26 M HMT+UVA at 1.8 J/cm
2. Forty-eight hours
later, cells were first stained with annexin V-FITC and PI, then subjected to fluorescence-activated cell sorter analyses to identify apoptotic cells. The x-
axis represents the staining level of annexin; the y-axis represents the staining level of PI. The lower right and upper right quadrants contain cells with
annexin positive cells indicating the apoptotic cell population. The cell lines used in this study are indicated on the left of the figure and the
treatment conditions are listed on top of the figure.
doi:10.1371/journal.pgen.1000189.g003
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results using the paired human ovarian cancer cells lines, these results
suggest that loss of MLH1 does not diminish the mutagenic potential
of triplex-directed psoralen ICLs in human cells, therefore MLH1
function is not required for the mutagenic processing of psoralen
ICLs in HeLa cells.
Psoralen ICL-Induced Mutations in MLH1-Proficient and -
Deficient Human Cell Lines
Randomly selected clones containing psoralen-ICL induced
mutations generated in the MLH1-proficient and MLH1-deficient
ovarian cancer cells were sequenced and are listed in Figure S5.
The mutants were selected from 3 different experiments. A total of
12 ICL-induced mutants obtained from the MLH1-proficient cells
were sequenced. There was more than one mutation in the same
colony in several cases. Ninety-two percent (11 of 12) of the
mutations screened occurred in the predicated psoralen interca-
lation and crosslinking site (A166T167). Of these, 42% of the
mutants (5 out of 12) consisted of T:A-A:T transversions at T167,
25% (3 of 12) contained A:T-T:A tranversions at A166, 17% (2 out
of 12) had T:A-G:C transversions at T167, one T:A-C:G
transversion at T167 was identified, and one of the mutants
consisted of a deletion containing the crosslinked site (Figure S5A).
As listed in Figure S5B, of the 14 mutants screened in the ICL-
containing plasmids transfected into the MLH1-deficient cells,
86% (12 out of 14) contained mutations in the predicted psoralen
crosslinking site. Of these, 29% (4 out 14) of the mutants contained
T:A-A:T transversions at T167, 29% (4 of 14) contained A:T-T:A
tranversions at A166, 14% (2 out of 14) had T:A-G:C transversions,
14% (2 out of 14) had single base deletions at T167, a single
insertion at T167 was identified, and one mutant consisted of a
deletion containing the crosslinked site. The mutation spectra
generated in MLH1-proficient and MLH1-deficient human cells
were very similar, suggesting that MLH1 is not required for this
type of psoralen ICL-induced mutagenesis. Therefore, MLH1
function is not required in the error-generating processing of
psoralen ICLs in these human cell lines.
Discussion
The formation of DNA ICLs can lead to cell death by
disrupting normal DNA functions such as replication and
transcription. This cell-killing capacity of ICL-inducing agents
has long been utilized in cancer therapy. However, ICL-inducing
agents can also cause genomic instability, which may eventually
lead to tumor formation. Genetic and biochemical studies have
revealed the importance of proteins from several repair pathways
in processing ICL lesions; these include proteins from the NER,
MMR, and HR mechanisms. It is important to understand the
functional significance of these proteins in both ICL-induced
cellular responses and mutagenesis. MSH2, the common protein
of MMR recognition complexes, plays important roles in both the
cytotoxicity of psoralen ICLs and their error-free repair in human
cells [4,5,47]. Since MLH1 functions downstream of MSH2 in
MMR, we hypothesized that MLH1 may also be involved in these
processes, which we have examined in this study.
Figure 4. PUVA-induced checkpoint signaling in MLH1-profi-
cient or MLH1-deficient cells. Lysates from MLH1-proficient (A2780)
and MLH1-deficient (A2780/cp70) cells 1 hour following control (no
treatment) or PUVA treatment (1610
26 M HMT+1.8 J/cm
2 UVA) were
probed for phosphorylation of ATR (at Ser428), CHK1 (at Ser345), ATM
(at Ser1981), CHK2 (at Thr68), total CHK1, total CHK2, and b-actin by
western blotting. Lane 1: MLH1-proficient cells with no treatment; lane
2: MLH1-deficient cells with no treatment; lane 3: MLH1-proficient cells
with PUVA treatment; lane 4: MLH1-deficient cells with PUVA treatment.
doi:10.1371/journal.pgen.1000189.g004
Figure 5. Psoralen ICL-induced mutagenesis in MLH1-profi-
cient or MLH1-deficient human cell lines. MLH1-proficient (A2780)
and MLH1-deficient cell lines (A2780/cp70) were transfected with the
pSupFG1 mutation reporter plasmid and mutations in the supF reporter
gene were measured 72 hours later. +UVA represents plasmid in the
presence of UVA irradiation only at 1.8 J/cm
2; pAG30+UVA represents
pSupFG1 plasmid treated with the specific psoralen-modified TFO
(pAG30) and then UVA irradiated at 1.8 J/cm
2; and pSCR30 represents
plasmid that was incubated with the psoralen-modified control
oligonucleotide and UVA irradiated at 1.8 J/cm
2. The bars represent
the standard errors of the means of three independent experiments.
The absolute mutation frequency is listed above each bar.
doi:10.1371/journal.pgen.1000189.g005
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Psoralen ICL in Human Cells
We have previously demonstrated that MSH2 deficiency
renders human cells more sensitive to psoralen ICLs [5]. Papouli
et al. (2004) have reported that MLH1-proficient and -deficient
human embryonic kidney cells show a similar level of sensitivity to
PUVA treatment under their conditions (53). In their study they
tested one concentration of psoralen (1 mM 4,59,8-trimethyl-
psoralen) and irradiated cells with 366 nm UVA at increasing
doses (0–20 J/cm
2). However, increasing the UVA dose may not
correspond to an increased number of ICLs. Akkari et al. (2000)
have demonstrated that increasing the concentrations of HMT
used to treat cells does result in increased levels of ICLs (40).
Therefore, in our study we varied the HMT concentrations (from
10
28 to 10
25 M), rather than the UVA dose (constant at 1.8 J/
cm
2). Our experimental results show that MLH1-deficient human
ovarian and cervical cancer cells are more resistant to psoralen
ICLs than isogenic MLH1-proficient cells. It is interesting that
deficiencies in MSH2 versus MLH1 have different effects on cell
survival in response to psoralen ICLs. This suggests that MSH2
and MLH1 have separate functions in response to DNA damage
in addition to their traditional roles defined in MMR. We
observed that MLH1, but not MSH2, is critical for psoralen ICL-
induced apoptosis, which may account for the difference in cell
survival between MSH2 and MLH1-deficient cells following
PUVA treatment. Our results demonstrate that MLH1 is required
for efficient activation of caspase 3/7, suggesting that MLH1 plays
an important role in activating these apoptosis effector proteins.
We have shown that MSH2 is involved in the recognition and
processing of psoralen ICLs in human cells [5]. Using triplex-
directed psoralen ICL substrates and purified human recombinant
proteins, we found that the human recombinant protein complex,
MutSb, can specifically bind to triplex-directed psoralen ICLs
(data not shown), which is consistent with data reported by Zhang
et al. (2002) [4], demonstrating that the human MutSb complex
can recognize psoralen ICLs. The interaction between the MSH2-
MSH3 complex and MLH1 may mediate the MLH1-dependent
apoptotic response to psoralen ICLs. Although we observed that
psoralen ICLs result in increased apoptosis in MSH2-deficient
cells and decreased apoptosis in MLH1-deficient cells (Figures 2
and 3), the increased apoptosis seen in MSH2-deficient cells may
be due to failure to repair the ICL damage. ICLs present a
formidable challenge to DNA metabolic activities, and may
activate subsequent apoptotic pathways. Unlike our results with
MSH2 [5], here we demonstrate that MLH1 function is not
required for the processing of psoralen ICLs (Figure S4). Given
that MSH2, but not MLH1 is involved in the recognition and
processing of psoralen ICLs, it is likely that a non-canonical MMR
function of MSH2, that circumvents a requirement for MLH1, is
employed during the repair of psoralen ICLs. This is consistent
with a previous report that processing of psoralen ICLs in
mammalian cell extracts is dependent upon MutSb, but is not
dependent on the presence of MLH1 [4]. Therefore, MSH2, but
not MLH1 is important for psoralen ICL repair in human cells.
This provides a possible explanation for the differences in cell
survival and apoptotic responses between MSH2- and MLH1-
deficient cells following PUVA treatment.
MLH1 Participates in Psoralen ICL-Induced Checkpoint
Signaling
MLH1 has been reported to function in DNA damage-induced
checkpoint signaling. For example, SN1 alkylating agents such as
MNNG can activate MSH2- and MLH1-dependent phosphoryla-
tion of CHK1 through ATR [36–38], and MMR-dependent G2/M
arrest by 6-TG signals through ATR-CHK1 [39]. In this study, we
found that MLH1 is involved in psoralen ICL-induced ATR,
CHK1, and CHK2 activation by phosphorylation. However,
psoralen ICLs represent complex DNA lesions that differ from
DNA damage induced by SN1 alkylating agents. For example,
studies have shown that proteins from several repair pathways
coordinately remove ICLs, including proteins from NER, MMR,
and recombination mechanisms.Ourresultssuggestthatitispossible
that the damage signal induced by psoralen ICLs can be passed to
MLH1 in the absence of MSH2. Therefore, the cellular signaling in
response to psoralen ICLs may differ from the signaling induced by
SN1 alkylating agents. ATM has been shown to be required for
phosphorylation of CHK2 at Thr68 in response to UV, ionizing
radiation (IR), and replication blocks induced by hydroxyurea [48].
It is interesting that we observed that psoralen ICLs can activate
ATM, but fail to activate CHK2 in MLH1-deficient cells. MSH2
and MLH1 have been shown to be required for CHK2 activation
and S-phase checkpoint activation in IR-irradiated human cells [32].
Both in vitro and in vivo approaches demonstrate that MSH2 can bind
to CHK2, and that MLH1 can associate with ATM [32]. The ATM
activation and lack of CHK2 phosphorylation at Thr68 in psoralen-
treated MLH1-deficient cells indicate that ATM requires MLH1,
perhaps to interact with MSH2 and CHK2. ATR activity has been
shown to be critical for a psoralen ICL-induced S-phase checkpoint
[42]. We show here that MLH1 function is also important for
psoralen ICL-induced checkpoint signaling. To our knowledge, this
is the first demonstration that MLH1 is involved in the cellular
response to psoralen ICLs in human cells.
Clinical Relevance of MSH2 and MLH1 Status in Tumor
Cells
Germline mutations in MSH2 and MLH1 together account for
nearly half of all hereditary non-polyposis colorectal cancer
(HNPCC) patients, of which ,60% of the mutations are in the
MLH1 gene, and ,35% in the MSH2 gene [49]. Previously, we
showed that MSH2 deficiency renders human cells more sensitive
to psoralen ICLs and reduces the error-free repair of these lesions.
Here we showed that MLH1 deficiency renders human cells more
resistant to ICLs, likely by disruption of ICL-induced activation of
apoptosis; and importantly, that MLH1 deficiency does not
diminish the mutagenic repair of psoralen ICLs. Therefore, when
treating tumors with ICL-inducing agents, the MSH2 and MLH1
status of the cells should be considered. For example, MSH2-
deficient cells may be more vulnerable to ICL-inducing agents
than MSH2-proficient cells, while MLH1-deficient cells have a
greater potential to survive treatment with mutagenic ICL-
inducing agents than MLH1-proficient cells, which may contrib-
ute to further tumor initiation.
Materials and Methods
Oligonucleotides and Mutation Reporter Plasmid,
pSupFG1
Oligonucleotides, each containing an HMT moiety on the 59
end and an amine group on the 39 end, were synthesized by the
Midland certified reagent company (Midland, TX). Both
pSupFG1 and p2RT plasmids contain a supF mutation reporter
gene, an ampicillin resistance gene, a pBR327 replication origin,
and an SV40 viral replication origin.
Cell Lines
A2780 (MLH1-proficient) and A2780/cp70 (MLH1-deficient)
cells lines were provided by Dr. R. J. Legerski (University of Texas
Roles of MMR Proteins in DNA Crosslink Repair
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obtained from Dr. R. F. Ozols (Fox Chase Cancer Center,
Pennsylvania, PA). Both cells lines were cultured in RPMI 1640
medium plus 10% fetal bovine serum (FBS). HeLa cells were
maintained in Dulbecco’s modified Eagle’s medium with 10%
FBS. The HEC59 (MSH2-deficient) cell line was cultured in
DMEM/F12 medium plus 10% FBS. The HEC59+Chr2 (MSH2-
proficient) cell line was maintained in DMEM/F12 medium
containing 100 mg/ml G418 and 10% FBS.
In Vitro Cytotoxicity Assays
The sensitivity of A2780 and A2780/cp70 cells to PUVA
treatment was evaluated using an MTT assay (tetrazolium salt
reduction, CellTiter 96 non-radioactive cell proliferation assay kit,
Promega, Madison, WI). Briefly, 2610
4 cells were seeded in 96-
well microplates in growth medium (100 ml) and incubated at
37uC in a humidified, 5% CO2 atmosphere. After 18 hours, the
medium was removed and replaced with serum-free medium
containing the corresponding concentrations of HMT (Sigma, St.
Louis, MO) previously dissolved in DMSO and diluted in serum-
free medium. After incubation in the dark for one hour, the cells
were UVA irradiated for 30 minutes at 1 mW/cm
2 to achieve a
dose of 1.8 J/cm
2. 15 W Cosmolux UVA lamps were used for
irradiation and Mylar filters were used to filter out UVB and UVC
irradiation (i.e. wavelengths ,315 nm). Ice was placed near the
cells and the temperature was maintained around 37uC during
irradiation. The serum-free medium containing HMT was
removed after irradiation and 100 ml growth medium was added
to each well after washing the cells once using 100 ml serum-free
medium. Triplicate cultures were established for each treatment.
Forty-eight hours after UVA irradiation, cell viability was
evaluated using an MTT assay. Viability was expressed as
percentage of mean absorbance for treated wells compared to
the mean absorbance for the control wells. Experiments were
performed in triplicate for statistical analysis of variance (ANOVA)
between MLH1-proficient and MLH1-deficient experimental
groups. Clonogenic assays were carried out as described in Nairn
et al [50]. PUVA treatment results in the production of both
psoralen monoadducts and crosslinks. Psoralen monoadducts are
efficiently processed by NER and since NER is functional in all
cell lines tested in this study, we expect that the MMR status of the
cells did not have a major effect in the response to PUVA-induced
monoadducts. In support of this idea, published work by other
groups suggest that loss of MMR has a minimal effect on UV-
induced cytotoxicity in transformed and tumor-derived cell lines
[51–53]. Since UV treatment results predominantly in intrastrand
DNA adducts that are substrates for NER, we might expect a
similar result with psoralen monoadducts.
Western Blotting
Cells were lysed in ice-cold buffer containing 50 mM Tris HCL
(pH 7.5), 1 mM EDTA, 10 mM DTT, 0.1% Triton X-100 and
Complete
TM proteinase inhibitor cocktail (Roche, Nutley, NJ).
Cell lysates (50–100 mg) were mixed with SDS gel-loading buffer
and heated at 95uC for 10 min, separated electrophoretically on a
7.5% or 10% SDS-polyacrylamide gel, and transferred to
polyvinylidene difluoride membranes (Bio-Rad Laboratories. Inc,
Hercules, CA). The blots were blocked for 1 hour in tris buffered
saline (TBS) containing 5% nonfat milk and 0.1% Tween 20. The
blots were then incubated with diluted primary antibody overnight
at 4uC. Primary antibodies used in this study include rabbit anti-
human MLH1 (Calbiochem, San Diego, CA), mouse anti-human
p-ATM (Ser1981), rabbit anti-human p-ATR (Ser428), p-CHK1
(Ser345), CHK1, p-CHK2 (Thr68), CHK2 (Santa Cruz Biotech-
nology, Santa Cruz, CA), mouse-anti human b-actin, rabbit anti-
human PCNA antibody, and rabbit anti-human GAPDH
polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz,
CA). The blots were washed three times with TBS containing
0.1% Tween 20 and incubated for 1 hour with horseradish
peroxidase-conjugated goat anti rabbit IgG or mouse IgG
secondary antibodies (Bio-Rad, Hercules, CA). After three washes
with TBS containing 0.1% Tween 20, bound secondary antibody
was detected by using an ECL detection reagent (Amersham,
Milano, Italy).
Caspase 3/7 Cleavage Assay
2610
4 cells were seeded in 96-well microplates in growth
medium (100 ml) and incubated at 37uC in a humidified, 5%
CO2 atmosphere. Eighteen hourslater,psoralen ICLs were induced
in the cells by PUVA treatment as described above. Triplicate
cultures were established for each treatment. Forty-eight hours after
UVA irradiation, the apoptotic status was evaluated by activation of
caspase-3/7 using the Apo-ONE homogeneous caspase-3/7 assay
(Promega, Madison, WI). The activation of caspase-3/7 is indicated
by cleavage of a caspase-3/7 substrate that can be measured by
fluorescence.Thelevelofapoptosiswasexpressedasa percentage of
mean fluorescence for each PUVA treated sample compared to the
mean fluorescence for the control sample.
Annexin V-FITC–Binding Assay and Fluorescence-
Activated Cell Sorter (FACS) Analysis
Annexin V-FITC apoptosis detection kit I (BD Biosciences
Pharmingen, San Diego, CA) was used to quantitatively measure
apoptotic cells. Forty-eight hours after treatment with 1610
26 M
HMT plus 1.8 J/cm
2 UVA irradiation, both floating and attached
cells were harvested. The cells were washed twice with ice cold
PBS and then resuspended in 16binding buffer [10 mM Hepes/
NaOH (pH 7.4) 140 mM NaCl, 2.5 mM CaCl2]a t1 610
6 cells/
ml. 200 ml of the solution (2610
5 cells) was transferred to a 5 ml
culture tube. Cells were gently vortexed and incubated with 10 ml
of annexin V-FITC and 10 ml of propidium iodide (PI) for 30 min
at room temperature (25uC) in the dark. 280 mlo f1 6 binding
buffer was added to each tube. Samples were analyzed on
Beckman-Coulter Ultra flow cytometer within one hour and
analyzed with Expo32 software. The instrument was set up with
an argon (488 nm) laser for excitation and a 525 nm pass filter for
the FITC label and a 630 nm pass filter for PI with appropriate
compensation. Annexin V-FITC is used to quantitatively deter-
mine the percentage of cells that are undergoing apoptosis, which
relies on the fact that cells lose membrane asymmetry in the early
phases of apoptosis. PI is a standard viability probe and is used to
distinguish viable from nonviable cells in FACS analysis. Viable
cells with intact membranes exclude PI, whereas the membranes
of dead and damaged cells are permeable to PI. Cells that stain
positive for annexin V-FITC and negative for PI are undergoing
apoptosis. Cells that stain positive for both annexin V-FITC and
PI are either in the end stage of apoptosis, are undergoing necrosis,
or are already dead. Cells that stain negative for both annexin V-
FITC and PI are alive and not undergoing measurable apoptosis.
Mutagenesis Assays
Psoralen crosslinked pSupFG1 plasmid was transfected into
human cells using Gene-PORTER transfection reagent (Gene
Therapy System, Inc. San Diego, CA). Approximately 5 mgo f
plasmid DNA was used per 5610
5 human cells. The cells were
incubated 48 hours prior to the isolation of the plasmid DNA. The
plasmid was subjected to DpnI restriction enzyme digestion to
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extraction, and transformation into E. coli MBM7070 indicator
strain, which carries an amber mutation in the LacZ gene.
Mutations in the supF gene can be detected using a blue/white
screen on 5-bromo-4-chloro-3-indolyl-B-D-galactoside, isopropyl
b-D-thiogalactoside, and ampicillin plates. The mutation frequen-
cy was determined as the number of mutant colonies (white
colonies) to the total number of colonies (blue+white colonies).
Experiments were performed in triplicate. DNA was isolated from
randomly selected colonies for DNA sequencing analysis.
Supporting Information
Figure S1 Downregulation of MLH1 expression by siRNA
treatment in HeLa cells. (A) The relative levels of MLH1 protein
are shown for cells treated with PBS, 100 nM control siRNA, or
100 nM MLH1-specific siRNA oligonucleotide at 24 hours,
48 hours and 72 hours after treatment. The bars represent the
standard errors of the means of protein expression assessed by
western blotting from four independent experiments. MLH1-
specific siRNA reduced MLH1 protein expression to ,29%
compared to a control non-targeting siRNA after 24 hours. Forty-
eight hours and 72 hours after the MLH1-specific siRNA
transfection, the remaining MLH1 level was ,13% and ,21%
of control, respectively. (B) Western blot showing the levels of
MLH1 protein following treatment with MLH1-specific siRNA
oligonucleotide on days 1, 2, and 3 during the mutagenesis assay.
GAPDH and PCNA protein levels were used as loading controls
for cytoplasm and nuclear proteins, respectively. HeLa cells were
transfected twice with 100 nM siRNA oligonucleotides on day 23
and day 0.
Found at: doi:10.1371/journal.pgen.1000189.s001 (2.92 MB TIF)
Figure S2 Sensitivity of MLH1 specific siRNA or control siRNA
oligonucleotide treated HeLa cells to PUVA treatment. Cell
viability was determined 48 hours after PUVA treatment using an
MTT assay performed in triplicate. The bars represent the
standard error of the means. **p,0.001, *p,0.01.
Found at: doi:10.1371/journal.pgen.1000189.s002 (8.91 MB TIF)
Figure S3 Nucleotide incorporation into plasmid, p2RT, in the
vicinity of TFO-targeted psoralen ICLs in MLH1-proficient or
MLH1-deficient human cell extracts. (A) Ethidium-bromide
stained gel; and (B) autoradiogram showing DNA synthesis
stimulated by ICL formation in the p2RT plasmid, as measured
by incorporation of radiolabeled nucleotides into a 190 bp
restricted fragment containing the psoralen ICL site. Lane 1:
p2RT plasmid incubated with MLH1-proficient cell extract; lane
2: p2RT containing a triplex-targeted ICL incubated with MLH1-
proficient cell extract; lane 3: p2RT plasmid incubated with
MLH1-deficient cell extract; lane 4: p2RT containing a triplex-
targeted ICL incubated with MLH1-deficient cell extract.
Found at: doi:10.1371/journal.pgen.1000189.s003 (2.00 MB TIF)
Figure S4 Psoralen ICL-induced mutagenesis in siRNA treated
HeLa cells. The mutation frequency of the supF gene was
determined as the ratio of the number of mutant colonies (white
colonies) to the total colonies (blue+white colonies). 2UVA
represents pSupFG1 without treatment; +UVA represents plasmid
in the presence of UVA irradiation at 1.8 J/cm
2; pAG30+UVA
represents pSupFG1 plasmid treated with the specific psoralen-
modified TFO (pAG30) at 10
26 M and then UVA irradiated at
1.8 J/cm
2; and pSCR30 represents plasmid that was incubated
with the psoralen-modified control oligonucleotide (10
26 M) and
UVA irradiated (1.8 J/cm
2). The bars represent the standard
errors of the means of three independent experiments.
Found at: doi:10.1371/journal.pgen.1000189.s004 (16.63 MB
TIF)
Figure S5 Psoralen-induced mutations in MLH1-proficient or
MLH1-deficient human ovarian cancer cell lines. Mutation
spectra of the psoralen ICL-induced mutations in the supF gene
in the (A) MLH1-proficient A2780 cell line, and (B) MLH1-
deficient A2780/cp70 cell line. Base substitutions are listed above
the supF gene sequence. Base deletions are indicated by a ‘2’. Base
insertions are indicated by a ‘+’. Multiple mutations in the same
plasmid are underlined and listed in the same line. The TFO-
binding site is underlined. The targeted TA site for psoralen ICL
formation is indicated by boldface type.
Found at: doi:10.1371/journal.pgen.1000189.s005 (16.79 MB
TIF)
Text S1 Supplemental text.
Found at: doi:10.1371/journal.pgen.1000189.s006 (0.06 MB
DOC)
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